Fontana spent more than two decades at the world’s largest medical device company, rising to the position of VP and general manager of the renal denervation (RDN) group that won FDA premarket approval for its Symplicity Spyral hypertension treatment in 2023.
“What do Philadelphia, Pennsylvania, Maple Grove, Minnesota, Bülach, Switzerland, and New Delhi, India have in common? They have all been stops along the way during my first month at Teleflex!” Fontana posted on LinkedIn.
He joins former Medtronic RDN and coronary leader Jason Weidman at Teleflex, where Weidman has led as president and CEO since June. In September, Teleflex added former Medtronic EVP and Cardiovascular Portfolio President Sean Salmon to its board of directors.
“Over the past several weeks, I’ve had the opportunity to meet incredible colleagues around the world, listen, learn, and see firsthand the passion and commitment they bring to improving patients’ lives,” Fontana said. ” I’ve walked away from every visit more energized than the last.
Different places. Different perspectives. One shared purpose.
“As a former soccer goalkeeper, and now the proud dad of one, I’ve always loved being part of a team,” he continued. “Whether on the soccer field or in medical device business, there is something special about people coming together, challenging each other, and working toward a common goal. And that is what makes me so excited about this next chapter.”
Fontana is also a member of Arrowfly’s new Medical Design & Outsourcing Medtech Innovation Board. Look for more from that initiative soon.
In September, Medtronic hired Lara Barghout, the former CEO and president of RDN developer Recor Medical, as president of the Interventional Cardiology Therapies (ICT) operating unit.
